ReviewNature reviews. Nephrology2013
Cardiorenal syndrome: pathophysiology and potential targets for clinical management.
Review in Nature reviews. Nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05927285 (Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1), which is not on this map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1
Who cites it
94 citing papers in PubMed, 187 citations in OpenAlex.
- Cardiorenal Syndrome and Depressive Symptoms: Exploring the Mood-Kidney Link With Heart Failure Risk in a Post-hoc Analysis of SPRINT.Kidney medicine · 2026Article
- A predictive model for the risk of death within 30 days in patients with cardiorenal syndrome treated with continuous renal replacement therapy: A retrospective study based on the MIMIC-IV database.Scientific reports · 2026Article
- A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome.Nature communications · 2026Article
- Article
- Diastolic dysfunction and the risk of end-stage kidney disease among patients with non-dialysis-dependent chronic kidney disease.The international journal of cardiovascular imaging · 2026Article
- Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.Current cardiology reports · 2026Review
- Potential host-gut microbiota-metabolite associations in cardiorenal syndrome progression: a multi-omics integrative analysis.BMC microbiology · 2026Article
- Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for All-Cause Mortality in Patients With Cardiovascular-Kidney-Metabolic Stage 4.Mediators of inflammation · 2026Article
- The promise of digital twins as a tool for personalized approaches in nephrology.Nature reviews. Nephrology · 2026Article
- Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms-a comprehensive review.Molecular and cellular biochemistry · 2025Review
- Mechanisms underlying atrial fibrillation in chronic kidney disease.Journal of molecular and cellular cardiology · 2025Review
- Sirtuins and Resveratrol in Cardiorenal Diseases: A Narrative Review of Mechanisms and Therapeutic Potential.Nutrients · 2025Review
- Cardiorenal syndrome: evolving concepts and pediatric knowledge gaps.Pediatric nephrology (Berlin, Germany) · 2025Review
- Article
- Acute kidney injury in acute heart failure-when to worry and when not to worry?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Review
- Clinically Evident Cardiopulmonary Congestion Does Not Significantly Impact the Prognosis of Patients With Septic Acute Kidney Injury.Journal of clinical medicine research · 2024Article
- Unsupervised Cluster Analysis in Patients with Cardiorenal Syndromes: Identifying Vascular Aspects.Journal of clinical medicine · 2024Article
- Article
- Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease.International journal of molecular sciences · 2024Review
- Eplerenone improves hyperglycemia and sympathetic excitation in chronic renocardiac syndrome in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined dysfunction of the heart and the kidneys, which can be associated with haemodynamic impairment, is classically referred to as cardiorenal syndrome (CRS). Cardiac pump failure with resulting volume retention by the kidneys, once thought to be the major pathophysiologic mechanism of CRS, is now considered to be only a part of a much more complicated phenomenon. Multiple body systems may contribute to the development of this pathologic constellation in an interconnected network of events. These events include heart failure (systolic or diastolic), atherosclerosis and endothelial cell dysfunction, uraemia and kidney failure, neurohormonal dysregulation, anaemia and iron disorders, mineral metabolic derangements including fibroblast growth factor 23, phosphorus and vitamin D disorders, and inflammatory pathways that may lead to malnutrition-inflammation-cachexia complex and protein-energy wasting. Hence, a pathophysiologically and clinically relevant classification of CRS based on the above components would be prudent. With the existing medical knowledge, it is almost impossible to identify where the process has started in any given patient. Rather, the events involved are closely interrelated, so that once the process starts at a particular point, other pathways of the network are potentially activated. Current therapies for CRS as well as ongoing studies are mostly focused on haemodynamic adjustments. The timely targeting of different components of this complex network, which may eventually lead to haemodynamic and vascular compromise and cause refractoriness to conventional treatments, seems necessary. Future studies should focus on interventions targeting these components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.